{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:40:08Z","timestamp":1784227208607,"version":"3.55.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.biopha.2018.08.101","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T14:14:24Z","timestamp":1535552064000},"page":"1218-1229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches"],"prefix":"10.1016","volume":"107","author":[{"given":"Kamal","family":"Dua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamshi Krishna","family":"Rapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakti Dhar","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Singhvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhur D.","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh Kumar","family":"Chellappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Satija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenu","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terezinha De Jesus Andreoli","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Hansbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1128\/CMR.16.3.463-496.2003","article-title":"Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence","volume":"16","author":"Smith","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2018.08.101_bib0010","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury","volume":"20","author":"Mittal","year":"2014","journal-title":"Antioxid. Redox Signal."},{"issue":"6","key":"10.1016\/j.biopha.2018.08.101_bib0015","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1089\/ars.2013.5447","article-title":"Are reactive oxygen species always detrimental to pathogens?","volume":"20","author":"Paiva","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.biopha.2018.08.101_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3164734","article-title":"The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults","volume":"2016","author":"Nita","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"6","key":"10.1016\/j.biopha.2018.08.101_bib0025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.freeradbiomed.2009.12.022","article-title":"Reactive oxygen species, cellular redox systems, and apoptosis","volume":"48","author":"Circu","year":"2010","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/21691401.2014.916715","article-title":"Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne","volume":"44","author":"Garg","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4046\/trd.2015.78.3.161","article-title":"Treatment of drug susceptible pulmonary tuberculosis","volume":"78","author":"Shin","year":"2015","journal-title":"Tuberc. Respir. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0040","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00061-2017","article-title":"Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses","volume":"50","author":"Ahmad Khan","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2018.08.101_bib0045","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.biopha.2018.05.099","article-title":"Microbiome as therapeutics in vesicular delivery","volume":"104","author":"Singhvi","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.biopha.2018.08.101_bib0050","doi-asserted-by":"crossref","first-page":"839","DOI":"10.4155\/fmc-2017-0245","article-title":"Immunological axis of curcumin-loaded vesicular drug delivery systems","volume":"10","author":"Chellappan","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.biopha.2018.08.101_bib0055","doi-asserted-by":"crossref","DOI":"10.23736\/S0031-0808.18.03428-6","article-title":"Novel drug delivery approaches in treating pulmonary fibrosis","author":"Dua","year":"2018","journal-title":"Panminerva Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.23736\/S0031-0808.18.03402-X","article-title":"Advancements in nano drug delivery systems: a challenge for biofilms in respiratory diseases","volume":"60","author":"Dua","year":"2018","journal-title":"Panminerva Med."},{"issue":"5","key":"10.1016\/j.biopha.2018.08.101_bib0065","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3109\/10717544.2015.1074765","article-title":"Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review","volume":"23","author":"Singh","year":"2016","journal-title":"Drug Deliv."},{"issue":"9","key":"10.1016\/j.biopha.2018.08.101_bib0070","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a017863","article-title":"Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis","volume":"5","author":"Seung","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"5","key":"10.1016\/j.biopha.2018.08.101_bib0075","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a017822","article-title":"Tuberculosis treatment and drug regimens","volume":"5","author":"Sotgiu","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"8933","key":"10.1016\/j.biopha.2018.08.101_bib0080","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(94)90693-9","article-title":"Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration","volume":"344","author":"Okwera","year":"1994","journal-title":"Lancet (London, England)"},{"issue":"7","key":"10.1016\/j.biopha.2018.08.101_bib0085","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1517\/17425247.2010.492212","article-title":"Micro- and nanocarrier-mediated lung targeting","volume":"7","author":"Kurmi","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2018.08.101_bib0090","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.biopha.2018.01.115","article-title":"Recent therapeutic approaches for the management of tuberculosis: challenges and opportunities","volume":"99","author":"Patil","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/45.1.77","article-title":"Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection","volume":"45","author":"Peters","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"issue":"1-2","key":"10.1016\/j.biopha.2018.08.101_bib0100","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ijpharm.2016.09.080","article-title":"Targeted delivery of rifampicin to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance of rifampicin-loaded poly(ester amide)s nanocarriers","volume":"513","author":"Amarnath Praphakar","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2018.08.101_bib0105","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S104395","article-title":"Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis","volume":"10","author":"Pinheiro","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2018.08.101_bib0110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.29252\/ibj.22.4.275","article-title":"Preparation and evaluation of rifampicin and Co-trimoxazole-loaded nanocarrier against Brucella melitensis infection","volume":"22","author":"Bodaghabadi","year":"2018","journal-title":"Iran. Biomed. J."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/ijmy.ijmy_162_17","article-title":"K.R. Uma Devi, Enhancing antimycobacterial activity of isoniazid and rifampicin incorporated norbornene nanoparticles","volume":"7","author":"Kumarasingam","year":"2018","journal-title":"Int. J. Mycobacteriol."},{"issue":"1-2","key":"10.1016\/j.biopha.2018.08.101_bib0120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijpharm.2012.11.042","article-title":"Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles","volume":"441","author":"Bhandari","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"2-3","key":"10.1016\/j.biopha.2018.08.101_bib0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0304-4165(96)00088-8","article-title":"Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice","volume":"1334","author":"Deol","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0130","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4103\/0250-474X.159602","article-title":"Formulation and characterization of pyrazinamide polymeric nanoparticles for pulmonary tuberculosis: efficiency for alveolar macrophage targeting","volume":"77","author":"Varma","year":"2015","journal-title":"Indian J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0135","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1038\/s41598-017-05453-3","article-title":"Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles","volume":"7","author":"Costa-Gouveia","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2018.08.101_bib0140","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s11095-016-1926-0","article-title":"Preparation and preclinical evaluation of inhalable particles containing rapamycin and anti-tuberculosis agents for induction of autophagy","volume":"33","author":"Gupta","year":"2016","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.colsurfb.2004.03.018","article-title":"Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin","volume":"36","author":"Makino","year":"2004","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"2","key":"10.1016\/j.biopha.2018.08.101_bib0150","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jconrel.2005.06.009","article-title":"Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages","volume":"107","author":"Zhou","year":"2005","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.biopha.2018.08.101_bib0155","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/AAC.34.6.967","article-title":"Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice","volume":"34","author":"Klemens","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.biopha.2018.08.101_bib0160","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/0970-2113.159559","article-title":"A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis","volume":"32","author":"Patil","year":"2015","journal-title":"Lung India"},{"issue":"12","key":"10.1016\/j.biopha.2018.08.101_bib0165","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1128\/AAC.37.12.2584","article-title":"In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis","volume":"37","author":"Mehta","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0170","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1128\/AAC.38.3.588","article-title":"Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice","volume":"38","author":"Agarwal","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.biopha.2018.08.101_bib0175","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1128\/AAC.40.11.2618","article-title":"Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin","volume":"40","author":"D\u00fczg\u00fcne\u015f","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.biopha.2018.08.101_bib0180","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.41.6.1211","article-title":"Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice","volume":"41","author":"Deol","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.biopha.2018.08.101_bib0185","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.42.2.459","article-title":"Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection","volume":"42","author":"Leitzke","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1-2","key":"10.1016\/j.biopha.2018.08.101_bib0190","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijpharm.2006.09.017","article-title":"Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis","volume":"330","author":"El-Ridy","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijantimicag.2007.08.008","article-title":"Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis","volume":"31","author":"Gaspar","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"7","key":"10.1016\/j.biopha.2018.08.101_bib0200","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/AAC.43.7.1638","article-title":"Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine","volume":"43","author":"Adams","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0205","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/pharmaceutics4030385","article-title":"Levofloxacin-proliposomes: opportunities for use in lung tuberculosis","volume":"4","author":"Rojanarat","year":"2012","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.biopha.2018.08.101_bib0210","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4103\/0110-5558.76435","article-title":"Niosome: a future of targeted drug delivery systems","volume":"1","author":"Kazi","year":"2010","journal-title":"J. Adv. Pharm. Technol. Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10717544.2013.868556","article-title":"Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety","volume":"22","author":"El-Ridy","year":"2015","journal-title":"Drug Deliv."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2018.08.101_bib0220","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijpharm.2013.12.034","article-title":"Inhaled solid lipid microparticles to target alveolar macrophages for tuberculosis","volume":"462","author":"Maretti","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2018.08.101_bib0225","first-page":"663","article-title":"Preparation and characterization of three tilmicosin-loaded lipid nanoparticles: physicochemical properties and in-vitro antibacterial activities","volume":"15","author":"Al-Qushawi","year":"2016","journal-title":"Iran. J. Pharm. Res.: IJPR"},{"issue":"4","key":"10.1016\/j.biopha.2018.08.101_bib0230","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tube.2004.11.003","article-title":"Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis (Edinb., Scotland)"},{"key":"10.1016\/j.biopha.2018.08.101_bib0235","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.chemphyslip.2015.09.008","article-title":"Characterization, biorecognitive activity and stability of WGA grafted lipid nanostructures for the controlled delivery of Rifampicin","volume":"193","author":"Pooja","year":"2015","journal-title":"Chem. Phys. Lipids"},{"issue":"5","key":"10.1016\/j.biopha.2018.08.101_bib0240","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s11095-014-1572-3","article-title":"Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery","volume":"32","author":"Song","year":"2015","journal-title":"Pharm. Res."},{"issue":"24","key":"10.1016\/j.biopha.2018.08.101_bib0245","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.2217\/nnm-2017-0248","article-title":"Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment","volume":"12","author":"Vieira","year":"2017","journal-title":"Nanomedicine (Lond., Engl.)"},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0250","first-page":"289","article-title":"Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives","volume":"2","author":"\u00dcner","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2018.08.101_bib0255","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.powtec.2015.12.037","article-title":"Pulmonary delivery of rifampicin microspheres using lower generation polyamidoamine dendrimers as a carrier","volume":"291","author":"Rajabnezhad","year":"2016","journal-title":"Powder Technol."},{"issue":"6","key":"10.1016\/j.biopha.2018.08.101_bib0260","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkg477","article-title":"Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis","volume":"52","author":"Pandey","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.biopha.2018.08.101_bib0265","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22101560","article-title":"Novel anti-tuberculosis nanodelivery formulation of ethambutol with graphene oxide","volume":"22","author":"Saifullah","year":"2017","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.biopha.2018.08.101_bib0270","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2147\/DDDT.S127897","article-title":"Rifapentine-linezolid-loaded PLGA microspheres for interventional therapy of cavitary pulmonary tuberculosis: preparation and in vitro characterization","volume":"11","author":"Huang","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2018.08.101_bib0275","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2147\/DDDT.S78407","article-title":"Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis","volume":"9","author":"Wu","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2018.08.101_bib0280","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s11427-016-5051-4","article-title":"Sustained release of isoniazid from polylactide microspheres prepared using solid\/oil drug loading method for tuberculosis treatment","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci. China Life Sci."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0285","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13346-016-0349-0","article-title":"Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases?","volume":"7","author":"Dua","year":"2017","journal-title":"Drug Deliv. Transl. Res."},{"issue":"6","key":"10.1016\/j.biopha.2018.08.101_bib0290","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21060702","volume":"21","author":"Alves","year":"2016","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"6","key":"10.1016\/j.biopha.2018.08.101_bib0295","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11095-018-2391-8","article-title":"Functionalization of PLGA nanoparticles with 1,3-beta-glucan enhances the intracellular pharmacokinetics of rifampicin in macrophages","volume":"35","author":"Tukulula","year":"2018","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.biopha.2018.08.101_bib0300","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1208\/s12249-018-0972-9","article-title":"Development of novel octanoyl chitosan nanoparticles for improved rifampicin pulmonary delivery: optimization by factorial design","volume":"19","author":"Petkar","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.biopha.2018.08.101_bib0305","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/370938","article-title":"Development of oral sustained release rifampicin loaded chitosan nanoparticles by design of experiment","volume":"2013","author":"Patel","year":"2013","journal-title":"J. Drug Deliv."},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0310","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2017.12.016","article-title":"Nanoparticle-Fusion Protein Complexes Protect against Mycobacterium tuberculosis Infection","volume":"26","author":"Hart","year":"2018","journal-title":"Mol. Ther."},{"issue":"13","key":"10.1016\/j.biopha.2018.08.101_bib0315","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201701395","article-title":"Advances and opportunities in nanoparticle- and nanomaterial-based vaccines against bacterial infections","volume":"7","author":"Lin","year":"2018","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.biopha.2018.08.101_bib0320","first-page":"1","article-title":"Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages","author":"Vieira","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0325","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12010-018-2695-5","article-title":"A novel approach in treatment of tuberculosis by targeting drugs to infected macrophages using biodegradable nanoparticles","volume":"185","author":"Shivangi","year":"2018","journal-title":"Appl. Biochem. Biotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0330","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ijpharm.2017.11.071","article-title":"Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis","volume":"536","author":"Vieira","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0335","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2014008285","article-title":"Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis","volume":"31","author":"Kaur","year":"2014","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"8","key":"10.1016\/j.biopha.2018.08.101_bib0340","doi-asserted-by":"crossref","first-page":"37","DOI":"10.15690\/vramn.v68i8.722","article-title":"Nanoparticles as drug delivery system for antituberculous drugs","author":"Sanzhakov","year":"2013","journal-title":"Vestnik Rossiiskoi akademii meditsinskikh nauk"},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0345","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MCP.0b013e32835eff08","article-title":"Advances in nanotechnology for diagnosis and treatment of tuberculosis","volume":"19","author":"Banyal","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"4-5","key":"10.1016\/j.biopha.2018.08.101_bib0350","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.addr.2009.11.023","article-title":"New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery","volume":"62","author":"Sosnik","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"18","key":"10.1016\/j.biopha.2018.08.101_bib0355","doi-asserted-by":"crossref","first-page":"9257","DOI":"10.1021\/acs.analchem.5b01761","article-title":"E-DNA sensor of Mycobacterium tuberculosis based on electrochemical assembly of nanomaterials (MWCNTs\/PPy\/PAMAM)","volume":"87","author":"Miodek","year":"2015","journal-title":"Anal. Chem."},{"issue":"5\u20136","key":"10.1016\/j.biopha.2018.08.101_bib0360","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.tube.2005.08.009","article-title":"Oral solid lipid nanoparticle-based antitubercular chemotherapy","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis (Edinb., Scotland)"},{"issue":"1\u20132","key":"10.1016\/j.biopha.2018.08.101_bib0365","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijpharm.2013.02.012","article-title":"Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH","volume":"446","author":"Singh","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2018.08.101_bib0370","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1128\/AAC.36.7.1374","article-title":"Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents","volume":"36","author":"Ranaldi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.biopha.2018.08.101_bib0375","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/10717544.2014.898110","article-title":"Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration","volume":"22","author":"Gaba","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2018.08.101_bib0380","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","article-title":"Nanostructured lipid carriers for site-specific drug delivery","volume":"103","author":"Khosa","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2018.08.101_bib0385","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S104395","article-title":"Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis","volume":"10","author":"Pinheiro","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2018.08.101_bib0390","doi-asserted-by":"crossref","first-page":"576","DOI":"10.2174\/187152711796235023","article-title":"Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain","volume":"10","author":"Beg","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.biopha.2018.08.101_bib0395","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jmgm.2015.05.012","article-title":"Association of the anti-tuberculosis drug rifampicin with a PAMAM dendrimer","volume":"60","author":"Bellini","year":"2015","journal-title":"J. Mol. Graph. Model."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0400","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/156720107779314794","article-title":"PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug","volume":"4","author":"Kumar","year":"2007","journal-title":"Curr. Drug Deliv."},{"issue":"8","key":"10.1016\/j.biopha.2018.08.101_bib0405","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/10611860600825159","article-title":"Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers","volume":"14","author":"Kumar","year":"2006","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0410","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/oli.1.1998.8.207","article-title":"Interaction of oligodeoxynucleotides with mycobacteria: implications for new therapeutic strategies","volume":"8","author":"Attia","year":"1998","journal-title":"Antisense Nucleic Acid Drug Dev."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0415","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1073\/pnas.97.1.418","article-title":"Treatment of mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate\/glutamine cell wall structure, and bacterial replication","volume":"97","author":"Harth","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0420","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8010007","article-title":"Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators","volume":"8","author":"Tandrup Schmidt","year":"2016","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0425","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4014\/jmb.1709.09009","article-title":"Potentiation of Th1-Type immune responses to Mycobacterium tuberculosis antigens in mice by cationic liposomes combined with De-O-Acylated lipooligosaccharide","volume":"28","author":"Ko","year":"2018","journal-title":"J. Microbiol. Biotechnol."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2018.08.101_bib0430","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijpharm.2017.04.074","article-title":"Preparation and characterization of isoniazid-loaded crude soybean lecithin liposomes","volume":"526","author":"Nkanga","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0435","first-page":"39","article-title":"Nanotechnology: advancing the translational respiratory research","volume":"9","author":"Dua","year":"2017","journal-title":"Interv. Med. Appl. Sci."},{"key":"10.1016\/j.biopha.2018.08.101_bib0440","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3389\/fmicb.2018.00602","article-title":"miRNAs in tuberculosis: new avenues for diagnosis and host-directed therapy","volume":"9","author":"Sabir","year":"2018","journal-title":"Front. Microbiol."},{"issue":"42","key":"10.1016\/j.biopha.2018.08.101_bib0445","doi-asserted-by":"crossref","first-page":"17408","DOI":"10.1073\/pnas.1112660108","article-title":"Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b","volume":"108","author":"Rajaram","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0450","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijmyco.2013.04.006","article-title":"Alteration of human macrophages microRNA expression profile upon infection with Mycobacterium tuberculosis","volume":"2","author":"Furci","year":"2013","journal-title":"Int. J. Mycobacteriol."},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0455","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1517\/17425247.2013.751370","article-title":"Targeted drug delivery to macrophages","volume":"10","author":"Jain","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2018.08.101_bib0460","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3389\/fimmu.2017.01499","article-title":"Host antimicrobial peptides: the promise of new treatment strategies against tuberculosis","volume":"8","author":"Arranz-Trull\u00e9n","year":"2017","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.biopha.2018.08.101_bib0465","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1073\/pnas.0603508103","article-title":"Inducing endogenous antimicrobial peptides to battle infections","volume":"103","author":"Zasloff","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.biopha.2018.08.101_bib0470","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/867381","article-title":"Antimicrobial peptides: their role as infection-selective tracers for molecular imaging","volume":"2014","author":"Ebenhan","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"10.1016\/j.biopha.2018.08.101_bib0475","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nri.2016.29","article-title":"The immunology of host defence peptides: beyond antimicrobial activity","volume":"16","author":"Hancock","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0480","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/092986611794578288","article-title":"Anti-tuberculosis activity of alpha-helical antimicrobial peptides: de novo designed L- and D-enantiomers versus L- and D-LL-37","volume":"18","author":"Jiang","year":"2011","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.biopha.2018.08.101_bib0485","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jconrel.2016.05.064","article-title":"Delivery of LLKKK18 loaded into self-assembling hyaluronic acid nanogel for tuberculosis treatment","volume":"235","author":"Silva","year":"2016","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.biopha.2018.08.101_bib0490","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fimmu.2016.00533","article-title":"Peptide IDR-1002 inhibits NF-\u03baB nuclear translocation by inhibition of I\u03baB\u03b1 degradation and activates p38\/ERK1\/2\u2013MSK1-Dependent CREB phosphorylation in macrophages stimulated with lipopolysaccharide","volume":"7","author":"Huante-Mendoza","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2018.08.101_bib0495","doi-asserted-by":"crossref","DOI":"10.1093\/database\/bay025","article-title":"AntiTbPdb: a knowledgebase of anti-tubercular peptides","volume":"2018","author":"Usmani","year":"2018","journal-title":"Database"},{"key":"10.1016\/j.biopha.2018.08.101_bib0500","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3389\/fimmu.2017.01499","article-title":"Host antimicrobial peptides: the promise of new treatment strategies against tuberculosis","volume":"8","author":"Arranz-Trullen","year":"2017","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2018.08.101_bib0505","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1128\/AAC.00427-13","article-title":"Improved efficacy of fosmidomycin against Plasmodium and Mycobacterium species by combination with the cell-penetrating peptide octaarginine","volume":"57","author":"Sparr","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"34","key":"10.1016\/j.biopha.2018.08.101_bib0510","doi-asserted-by":"crossref","first-page":"10945","DOI":"10.1021\/jacs.6b04831","article-title":"Dual targeting of intracellular pathogenic Bacteria with a cleavable conjugate of kanamycin and an antibacterial, cell penetrating peptide","volume":"138","author":"Brezden","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"10.1016\/j.biopha.2018.08.101_bib0515","first-page":"3540","article-title":"Cell penetrating synthetic antimicrobial peptides (SAMPs) exhibiting potent and selective killing of mycobacterium by targeting its DNA","volume":"21","author":"Sharma","year":"2015","journal-title":"Chemistry (Weinheim an der Bergstrasse, Germany)"},{"key":"10.1016\/j.biopha.2018.08.101_bib0520","doi-asserted-by":"crossref","first-page":"20832","DOI":"10.1038\/srep20832","article-title":"Impact of different cell penetrating peptides on the efficacy of antisense therapeutics for targeting intracellular pathogens","volume":"6","author":"Abushahba","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2018.08.101_bib0525","doi-asserted-by":"crossref","first-page":"11719","DOI":"10.1038\/srep11719","article-title":"Discovery of a non-cationic cell penetrating peptide derived from membrane-interacting human proteins and its potential as a protein delivery carrier","volume":"5","author":"Young Kim","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2018.08.101_bib0530","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.drudis.2016.09.010","article-title":"Identification and validation of novel drug targets in Mycobacterium tuberculosis","volume":"22","author":"Singh","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"26","key":"10.1016\/j.biopha.2018.08.101_bib0535","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.2174\/1381612043383223","article-title":"Identification and validation of novel drug targets in tuberculosis","volume":"10","author":"Duncan","year":"2004","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.biopha.2018.08.101_bib0540","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.compbiolchem.2005.07.001","article-title":"Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis","volume":"29","author":"Anishetty","year":"2005","journal-title":"Comput. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0545","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"issue":"18","key":"10.1016\/j.biopha.2018.08.101_bib0550","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1093\/nar\/gkw625","article-title":"Investigating essential gene function in Mycobacterium tuberculosis using an efficient CRISPR interference system","volume":"44","author":"Singh","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2018.08.101_bib0555","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fcimb.2017.00240","article-title":"Role of bacterioferritin & ferritin in M. Tuberculosis pathogenesis and drug resistance: a future perspective by interactomic approach","volume":"7","author":"Sharma","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.biopha.2018.08.101_bib0560","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2015.06.005","article-title":"Mycolic acids, a promising mycobacterial ligand for targeting of nanoencapsulated drugs in tuberculosis","volume":"211","author":"Lemmer","year":"2015","journal-title":"J. Controlled Release"},{"issue":"2","key":"10.1016\/j.biopha.2018.08.101_bib0565","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jconrel.2003.11.013","article-title":"Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs","volume":"95","author":"Prabakaran","year":"2004","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.biopha.2018.08.101_bib0570","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-107-4-526","article-title":"Oxygen radicals and human disease","volume":"107","author":"Cross","year":"1987","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0575","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1440-1843.2008.01447.x","article-title":"Impact of oxidative stress on lung diseases","volume":"14","author":"Park","year":"2009","journal-title":"Respirology (Carlton, Vic.)"},{"issue":"1","key":"10.1016\/j.biopha.2018.08.101_bib0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029631","article-title":"Vitamins A & D inhibit the growth of mycobacteria in radiometric culture","volume":"7","author":"Greenstein","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2018.08.101_bib0585","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/ncomms2898","article-title":"Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction","volume":"4","author":"Vilcheze","year":"2013","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2018.08.101_bib0590","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1089\/jir.2014.0210","article-title":"Liposomal glutathione supplementation restores TH1 cytokine response to Mycobacterium tuberculosis infection in HIV-Infected individuals","volume":"35","author":"Ly","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"issue":"6","key":"10.1016\/j.biopha.2018.08.101_bib0595","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1128\/IAI.69.6.3562-3568.2001","article-title":"Mycobacterium bovis BCG recA deletion mutant shows increased susceptibility to DNA-damaging agents but wild-type survival in a mouse infection model","volume":"69","author":"Sander","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.biopha.2018.08.101_bib0600","doi-asserted-by":"crossref","DOI":"10.1002\/iub.1867","article-title":"Redox-guided small molecule antimycobacterials","author":"Kulkarni","year":"2018","journal-title":"IUBMB Life"},{"key":"10.1016\/j.biopha.2018.08.101_bib0605","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12931-015-0223-5","article-title":"Nanotechnology in respiratory medicine","volume":"16","author":"Omlor","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.biopha.2018.08.101_bib0610","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3389\/fmicb.2017.02452","article-title":"Repurposing and revival of the drugs: a new approach to combat the drug resistant tuberculosis","volume":"8","author":"Sharma","year":"2017","journal-title":"Front. Microbiol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218338009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218338009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:15:11Z","timestamp":1766024111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218338009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":122,"alternative-id":["S0753332218338009"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.08.101","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.08.101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}